7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Otitis Media

Conditions

Otitis Media, Pneumococcal Infections

Trial Timeline

Mar 1, 1995 → Mar 1, 1999

NCT ID

NCT00378417

About 7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine

7-valent pneumococcal-CRM197 conjugate vaccine + 7-valent pneumococcal-OMPC conjugate vaccine is a phase 3 stage product being developed by Merck for Otitis Media. The current trial status is completed. This product is registered under clinical trial identifier NCT00378417. Target conditions include Otitis Media, Pneumococcal Infections.

What happened to similar drugs?

2 of 11 similar drugs in Otitis Media were approved

Approved (2) Terminated (2) Active (7)

🔄ofloxacin otic solution 0.3%Daiichi SankyoPhase 3

🔄levofloxacinJohnson & JohnsonPhase 3

🔄levofloxacin; amoxicillin/clavulanateJohnson & JohnsonPhase 3

🔄V114MerckPhase 3

✅Montelukast + PlaceboMerckApproved

🔄ZmaxPfizerPhase 3

✅Saline + Fentanyl + Dexmedetomidine + DexmedetomidinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00378417	Phase 3	Completed	Mar 1, 1995	Mar 1, 1999	Otitis Media

Competing Products

15 competing products in Otitis Media

See all competitors

Product	Company	Stage	Hype Score
piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1% + piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1% + piperacillin 2% + tazobactam 0.25% + piperacillin 4% + tazobactam 0.5% + piperacillin 8% + tazobactam 1.0%	Yuhan	Phase 1/2	24
ofloxacin otic solution 0.3%	Daiichi Sankyo	Phase 3	40
levofloxacin	Johnson & Johnson	Phase 3	40
levofloxacin; amoxicillin/clavulanate	Johnson & Johnson	Phase 3	40
V114	Merck	Phase 3	40
Montelukast + Placebo	Merck	Approved	43
Prevenar	Pfizer	Pre-clinical	26
Zmax	Pfizer	Phase 3	40
Observational	Pfizer	Pre-clinical	26
Saline + Fentanyl + Dexmedetomidine + Dexmedetomidine	Pfizer	Approved	43
amoxicillin/clavulanate postassium (Augmentin ES-600) + azithromycin SR	Pfizer	Phase 3	40
60 mg/kg azithromycin ER + 30 mg/kg azithromycin IR	Pfizer	Phase 2	35
Telithromycin (HMR3647)	Sanofi	Phase 3	40
telithromycin (HMR3647)	Sanofi	Phase 3	32
Telithromycin + Azithromycin	Sanofi	Phase 3	32